Lilly Discontinues Several Insulin Products: What Patients Need to Know

October 10, 2025, 12:49:43 PM – Eli Lilly and Company announced on October 8, 2024, that it will discontinue several of its insulin products in⁤ the United States. This decision, while part of a broader ‍portfolio rationalization, impacts access to vital medications for people living with diabetes and requires careful attention from patients and healthcare providers.

Which Insulins Are Being⁢ Discontinued?

The following Lilly insulins are slated for discontinuation: Insulin Lispro, Insulin Lispro Protamine, and Insulin Lispro Mix 50/50. These products⁤ are available in⁣ vial‍ and pen formulations. The company plans to cease shipping these products in the coming months, with complete removal from the market expected by the end of 2025.

Why Is Lilly Making This Change?

Lilly stated the decision is driven by a desire to streamline its insulin portfolio and focus on newer, innovative treatments. The company is prioritizing the advancement and distribution of next-generation insulins designed to offer improved efficacy and convenience. This is a ⁤common practice in the pharmaceutical industry as companies adapt to evolving medical needs and market dynamics.

What Does This Mean for Patients?

The discontinuation of these insulins presents challenges for patients⁣ who currently rely⁣ on them. Individuals using these products will need to consult with their healthcare ⁤provider to transition to an alternative insulin regimen. This transition should be carefully managed to ensure stable blood glucose control.

Transitioning to‍ a New Insulin

Your doctor will consider several factors‍ when recommending a new insulin,including your type of diabetes,current insulin dosage,lifestyle,and insurance⁤ coverage. It’s crucial to have an open discussion about your concerns and preferences during this process. Don’t ⁢hesitate to ask questions about potential side effects, cost, and how to adjust your dosage.

“The American Diabetes association is committed to ensuring that everyone with diabetes has access to affordable and effective insulin. We are monitoring the situation ⁢closely ⁣and will provide ‍guidance to patients and healthcare professionals as needed.”

Potential Challenges and Solutions

one potential challenge ⁢is finding an equivalent insulin that is covered by your insurance plan. Formulary changes can impact medication costs,so it’s essential to verify coverage before switching. ‍ If you experience financial hardship, resources like NeedyMeds can help you find patient assistance programs.

Another concern ‍is the potential for increased⁣ demand for alternative insulins, which could lead⁢ to temporary shortages.Lilly has stated it is working to mitigate this risk by increasing ⁤production of its remaining insulin products. Patients should proactively refill prescriptions to avoid potential disruptions.

Resources for Patients and Healthcare Providers

Lilly has⁢ established a dedicated support line to assist patients and healthcare providers with the⁢ transition. You can reach them at 1-800-LillyRx (1-800-545-5979).‍ The ⁣ American Diabetes ⁤Association and JDRF also offer valuable⁤ resources and support for ‍people with diabetes.